An intravenous malaria vaccine was found to be effective in a small clinical trial. Maryland-based biotech company Sanaria developed the PfSPZ vaccine from sporozoites, an immature stage of the malarial parasite Plasmodium falciparum. A study in the journal Science reported that among the 15 participants who were administered high doses of the vaccine, 12 have shown complete immunity to the infectious disease. However, administering the intravenous vaccine may be challenging on a larger scale, compared with injected and oral vaccines that are given promptly.

Full Story:

Related Summaries